6 active not recruiting. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 6 |
| Phase 1 | 3 | Active not recruiting 3 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) BLU-808, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Active not recruiting | Blueprint Medicines Corporation | 105 | 2025-05-28 | 2026-07-22 |
| A Phase 2 in Adult Subjects With Hereditary Angioedema BW-20805 - Hereditary Angioedema (HAE) | Phase 2 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 25 | 2025-02-28 | 2026-04-17 |
| A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema STAR-0215 - Hereditary Angioedema | Phase 2 | Active not recruiting | Astria Therapeutics, Inc. | 56 | 2023-09-26 | 2025-07-23 |
| Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients ADX-324, Placebo - Hereditary Angioedema | Phase 1 / Phase 2 | Active not recruiting | ADARx Pharmaceuticals, Inc. | 53 | 2022-12-14 | 2026-06-16 |
| A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331 - Hereditary Angioedema, HAE | Phase 1 / Phase 2 | Active not recruiting | BioMarin Pharmaceutical | 44 | 2022-02-15 | 2024-05-16 |
| NTLA-2002 in Adults With Hereditary Angioedema (HAE) Biological NTLA-2002, Normal Saline IV Administration - Hereditary Angioedema | Phase 1 / Phase 2 | Active not recruiting | Intellia Therapeutics | 37 | 2021-12-10 | 2026-09-25 |
Angioedemas, Hereditary (5) · Angioedema (1) · Chronic Inducible Urticaria (1) · Chronic Urticaria (1) · Cold Urticaria (1) · Familial dermographism (1)
Hypersensitivity (6) · Hypersensitivity, Immediate (6) · Immune System Diseases (6) · Skin Diseases (6) · Skin Diseases, Vascular (6) · Skin and Connective Tissue Diseases (6) · Cardiovascular Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Hereditary Complement Deficiency Diseases (5) · Immunologic Deficiency Syndromes (5) · Primary Immunodeficiency Diseases (5) · Vascular Diseases (5) · Angioedema (4)
RNA, Small Interfering (1) · Sodium Chloride (1)
ADARx Pharmaceuticals, Inc. (1) · Astria Therapeutics, Inc. (1) · BioMarin Pharmaceutical (1) · Blueprint Medicines Corporation (1) · Intellia Therapeutics (1) · Shanghai Argo Biopharmaceutical Co., Ltd. (1)
Germany (4) · United States (4) · Australia (3) · Spain (3) · Italy (2) · Poland (2) · United Kingdom (2) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Netherlands (1) · New Zealand (1)
Lauge Farnaes, MD (1) · Markus Magerl, Doctor (1)
2023 (1)